JB Chemicals & Pharmaceuticals Ltd (JB Pharma), one of the fastest growing pharmaceutical companies in India, announced its financial results for the quarter ended 30th June 2025.

The company recorded revenue of Rs. 1,094 crores in the first quarter of FY26, registering growth of 9% from Rs. 1,004 crores in Q1 FY25. Operating EBITDA (Earnings before Interest, Depreciation and Taxes) increased by 13% to Rs. 330 crores compared to Rs. 292 crores in the same quarter last year. Net profit rose by 14% to Rs. 202 crores versus Rs. 177 crores in Q1 FY25.

Commenting on the financial results, Nikhil Chopra, CEO and Wholetime Director, JB Pharma stated: “JB continues to be the fastest growing domestic pharma company amongst top 25 organizations as per IQVIA MAT Jun’25 data. The domestic business recorded approx. 14% value growth. This was driven by acute and chronic segments, including our ophthalmology portfolio. Our major brands &  their franchises are also performing well. The CDMO business momentum is likely to sustain in coming quarters.  Our Operating EBITDA margins crossed 30% for the first time, which highlights the results of our strategy of focusing on profitable growth.

“Going forward, we will maintain focus on driving topline growth, cost optimization and organizational efficiencies. I am confident that the organization will continue to perform well, with our domestic and CDMO segments leading the way on growth and profitability. We have all the necessary building blocks in place for sustainable growth in the coming years.”

The company said its domestic formulations business recorded revenue of Rs. 678 crore as against Rs. 595 crore in the first quarter last fiscal year, up 14 per cent driven by good growth in acute including opthal portfolio and the chronic portfolio.

International business revenue declined marginally to Rs. 283 crore in the first quarter as compared to Rs. 290 crore in the year-ago period, it added.